“Biotech is becoming increasingly important to the mainstream chemical industry as the demand for more sustainable solutions intensifies. Biotech is especially well-suited to help with some of the industry’s biggest challenges”. To say it – in this exclusive interview with Il Bioeconomista – is Christophe Schilling, founder and CEO of Genomatica, a widely-recognized bioengineering leader for the chemical industry. The San Diego-based biotechnology company develops and licenses bio-based manufacturing processes for the production of intermediate and basic chemicals.
Since being named CEO in May 2009, Christophe Schilling has led Genomatica to widespread recognition as a leader in industrial biotechnology, with a commercialized first process, top-tier licensees, strong investors and an unrivaled string of awards for engineering (Kirkpatrick), science (EPA Presidential Green Chemistry), industry leadership (voted #1 Hottest three years in a row by Biofuels Digest), and company culture (The Scientist as a Best Place to Work). Schilling frequently speaks on industry trends at major conferences and serves as a member of the World Economic Forum Global Agenda Council on Biotechnology.
Ginkgo Bioworks and Genomatica announced an alliance to more rapidly deliver biology-based solutions for the world’s highest-volume intermediate and specialty chemicals. Mainstream chemical producers can now in-license technology to manufacture their widely-used chemicals with cost-effective and sustainable whole-process solutions that include engineered microorganisms, complete process designs and technology transfer support. The alliance is structured as a deep collaboration, with two-way sharing of technology and intellectual property, along with joint technology development, to provide a single unified offering to the market.
Mater Biotech, a 100% company owned by Novamont, today proved Genomatica’s revolutionary technology that converts renewable feedstocks into 1,4 butendiol (BDO) at the Grand Opening of its first commercial bio-BDO plant in Bottrighe di Adria (Rovigo, Italy).
Novamont’s bio-based butanediol (BDO) plant in Bottrighe di Adria (Veneto, North-eastern Italy), established as a joint venture (Mater Biotech) with San Diego-based Genomatica and now entirely controlled by the company headquartered in Novara, will come on stream by the end of September. It is a big step forward for the Italian bioeconomy, which is confirmed in its leading role in Europe.
BASF and Genomatica have expanded the scope of their license agreement for the production of 1,4-butanediol based on renewable feedstock (renewable BDO) using Genomatica’s patented process. The parties added certain countries in Southeast Asia to their initial agreement, which focused on North America.
Genomatica and Cargill have entered into a collaboration agreement to accelerate the production of renewable chemicals for industrial applications. The collaboration will give chemical producers, distributors and users access to a reliable, cost-effective source of carbohydrate feedstocks, co-location support services and production partnerships, based on GENO™ process technologies.
Genomatica, US industrial biotech company, announced that major nylon intermediates – including hexamethylenediamine, caprolactam and adipic acid (HMD, CPL and ADA) – are the focus of its third publicly-disclosed development program.
Genomatica is developing complete process technologies for the biobased production of these intermediates, which it will then license to major firms in the nylon value chain. These three chemicals, with a total market of over $18 billion per year, are used primarily in the production of nylon 6 and nylon 6,6, also referred to as the polyamides PA 6 and PA 6,6.
Braskem, the largest petrochemical producer in the Americas and the world’s leading biopolymer producer, and Genomatica, a U.S. biotechnology company, have signed an agreement for the joint development of a new technology for the production of butadiene from renewable feedstocks. Through this partnership, Braskem reaffirms its commitment to invest in the research of producing chemicals from renewable feedstocks, effectively strengthening its leadership role in this segment.
Versalis (Group Eni) and Genomatica announced the signing of a definitive joint development and licensing agreement to establish a technology joint venture for bio-based butadiene.
The two companies will work together to develop a complete ”end-to-end’ process for the production of butadiene from non-food biomass.
The resulting process will be licensed across Europe, Asia and Africa by the newly-created joint venture. Future Licensees of the process, including Versalis, will provide the capital required for the construction and operation of their own plants, and be responsible for the use and sale of the resulting butadiene.
Versalis will provide over $20 million in funding to Genomatica to support development of the integrated end-to-end process. It will also aim to be the first to license the process and build commercial plants.